<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722355</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 9006</org_study_id>
    <nct_id>NCT03722355</nct_id>
  </id_info>
  <brief_title>Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma</brief_title>
  <official_title>A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperfractionated radiation therapy (RT) to 72.0 Gy with BCNU will be compared to
      conventional radiation therapy to 60.0 Gy with BCNU to determine if hyperfractionated RT can
      improve the median survival time of adults with supratentorial malignant gliomas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 1990</start_date>
  <completion_date type="Actual">October 18, 2002</completion_date>
  <primary_completion_date type="Actual">March 15, 1994</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization to the date of death or last follow up, assessed up to 131 months.</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">712</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Conventional RT + Carmustine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Hyperfractionated RT + Carmustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional RT</intervention_name>
    <description>Radiation therapy</description>
    <arm_group_label>Arm 1: Conventional RT + Carmustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated RT</intervention_name>
    <description>Radiation therapy</description>
    <arm_group_label>Arm 2: Hyperfractionated RT + Carmustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Arm 1: Conventional RT + Carmustine</arm_group_label>
    <arm_group_label>Arm 2: Hyperfractionated RT + Carmustine</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Gliadel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed glioblastoma multiforme (with areas of necrosis),
             malignant astrocytoma and astrocytoma with foci of anaplasia

          -  Karnofsky Performance Score ≥ 60

          -  Absolute Neutrophil count ≥ 1,500

          -  Platelets ≥ 100,000

          -  BUN ≤ 25

          -  Creatinine ≤ 1.5

          -  Bilirubin ≤ 2.0

          -  Hemoglobin ≥ 10 gm

          -  SGOT &lt; 2 x upper limit of normal

          -  SGPT &lt; 2 x upper limit of normal

        Exclusion Criteria:

          -  No prior radiation to the head or neck area, chemotherapy or radiosensitizer

          -  No malignancy with the past five years except non-melanomatous skin cancer or
             carcinoma in-situ of the cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter J Curran, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Therapy Oncology Group</affiliation>
  </overall_official>
  <link>
    <url>https://nctn-data-archive.nci.nih.gov/</url>
    <description>Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive.</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>Astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

